Nanobiotix S.A. is a biotechnology company focused on developing innovative treatments for cancer by utilizing its proprietary nanotechnology platform
The company aims to enhance the effectiveness of cancer therapies through its lead product candidate, which is designed to improve the tumor's response to radiation therapy. By harnessing the unique properties of nanoparticles, Nanobiotix aspires to provide targeted, localized treatments that minimize damage to surrounding healthy tissue, ultimately improving patient outcomes and quality of life in the fight against cancer.
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to $24.82 in pre-market trading
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ: LOGI) fell in today’s pre-market trading.
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on Tuesday.
Nanobiotix SA - ADR (NASDAQ: NBTX) shares are trading lower by 16.4% to $5.14 Thursday morning after the company priced its global follow-on offering. The offering includes 3,106,907 ADSs in the U.S.
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday.
